Researchers from the Karolinska Institutet and Louisiana State University (LSU) Health New Orleans have published an article describing positive effects of intranasal delivery of a cocktail of five different pro-resolving lipid mediators in a mouse model of Alzheimer’s Disease, including improvements in cognitive function. The article, titled “Intranasal delivery of pro-resolving lipid mediators rescues memory and gamma oscillation impairment in AppNL-G-F/NL-G-F mice” was published in the Nature journal Communications Biology.
The authors acknowledge that they are uncertain whether the effects observed resulted from delivery of the lipid mediators across the blood-brain barrier; “However,” they say, “the intranasal route is known for its ability to channel substances to the brain and the detection of deuterium-labelled LMs in the brain support that the effects observed in the present study were direct.” In any event, they add, “mediation of beneficial effects into the brain from the periphery should not be disregarded as an important component of a treatment effect.”
The researchers conclude that, “that intranasal delivery is a non-invasive administration route for LMs that has an impact on the central nervous system” and that “this study supports the potential therapeutic intranasal delivery of LMs in AD, other neurodegenerative diseases, and various forms of brain injury.”
According to LSU Health New Orleans, one of the lipid mediators used in the study, Neuroprotectin D1 (NPD1), from the lab of LSU Health professor Nicolas Bazan, has previously been shown to be deficient in brains of Alzheimer’s patients and demonstrated protective effects against stroke and retinal damage.
Read the Communications Biology article.
Read the LSU press release.
